SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2018

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 17. SUBSEQUENT EVENTS

The following subsequent event occurred in August 2018:

In October 2013, we sold our interests in royalty and milestone payments under our license agreements relating to our Acuform technology in the Type 2 diabetes therapeutic area to PDL BioPharma, Inc. (PDL) for $240.5 million.  On August 2, 2018 we sold our remaining interest in such payments to PDL for $20.0 million, consisting of an upfront payment of $10.0 million in cash and an additional $10.0 million in cash upon the satisfaction of certain conditions.